| 000 | 01696 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513045540.0 | ||
| 264 | 0 | _c19950316 | |
| 008 | 199503s 0 0 eng d | ||
| 022 | _a0163-2116 | ||
| 024 | 7 |
_a10.1007/BF02065413 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiner, P | |
| 245 | 0 | 0 |
_aSafety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. _h[electronic resource] |
| 260 |
_bDigestive diseases and sciences _cFeb 1995 |
||
| 300 |
_a296-304 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAminosalicylic Acids _xadverse effects |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xadverse effects |
| 650 | 0 | 4 | _aCapsules |
| 650 | 0 | 4 |
_aColitis, Ulcerative _xdrug therapy |
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMesalamine |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSafety |
| 650 | 0 | 4 | _aStatistics, Nonparametric |
| 650 | 0 | 4 |
_aSubstance Withdrawal Syndrome _xepidemiology |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aHanauer, S | |
| 700 | 1 | _aRobinson, M | |
| 700 | 1 | _aSchwartz, J | |
| 700 | 1 | _aArora, S | |
| 773 | 0 |
_tDigestive diseases and sciences _gvol. 40 _gno. 2 _gp. 296-304 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF02065413 _zAvailable from publisher's website |
| 999 |
_c7850530 _d7850530 |
||